- Home
- BFRI vs GTBP Comparison
BFRI vs GTBP Comparison
Compare BFRI & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BFRI | GTBP |
|---|---|---|
| Founded | 1997 | 1965 |
| Country | United States | United States |
| Employees | 93 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.6M | 12.1M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | BFRI | GTBP |
|---|---|---|
| Price | $0.85 | $0.47 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $2.75 | N/A |
| AVG Volume (30 Days) | 480.9K | ★ 823.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.75 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $11.37 | N/A |
| Revenue Next Year | $10.96 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.54 | $0.40 |
| 52 Week High | $1.18 | $3.73 |
Technical Indicators
Market Signals| Indicator | BFRI | GTBP |
|---|---|---|
| Relative Strength Index (RSI) | 46.11 | 38.30 |
| Support Level | $0.81 | $0.41 |
| Resistance Level | $0.91 | $0.59 |
| Average True Range (ATR) | 0.07 | 0.05 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 46.44 | 18.36 |
Price Performance
Historical ComparisonAbout BFRI Biofrontera Inc.
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions.
About GTBP GT Biopharma Inc.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.